CliffBio
biologic

Lantidra

donislecel-jujn

Loss of exclusivityJune 2035projected — 12-year biologic exclusivity estimate
CompanyCellTrans →See this company's full patent-cliff portfolio

Drug detail

Brand nameLantidra
Active ingredientdonislecel-jujn
Strength1X10E6EQUIVALENT ISLET NUMBER (EIN)
Dosage formSuspension
RouteIntravenous
ModalityBiologic
FDA approvalJune 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lantidra patent cliff — loss of exclusivity June 2035 | CliffBio